Ligand Pharmaceuticals Inc. filings document the regulatory record for a Nasdaq-listed biopharmaceutical royalty aggregator with common stock trading under LGND. The company’s disclosures cover royalty portfolio economics, technology licenses, partner-product clinical and regulatory matters, operating results, milestone payments, commercial royalties, Captisol® material sales, and NITRICIL™ licensing.
Ligand’s SEC record also includes Form 8-K reports on material agreements, license-program rights, credit-agreement amendments, Regulation FD communications, capital-structure disclosures, and financial results. Proxy materials describe board matters, shareholder voting items, executive compensation, equity awards, and governance practices for the public company.
Ligand Pharmaceuticals filed an update explaining that it has posted materials about its private placement investment in Athira Pharma, Inc. on its investor relations website and certain social media accounts. These posts provide more detail on the investment for interested readers.
The company also reiterates how it shares important information with the public. Ligand states that material updates may appear through SEC filings, its investor relations site, press releases, public conference calls, webcasts, its X (Twitter) account @Ligand_LGND and its LinkedIn page. Investors and other stakeholders are encouraged to review these channels regularly, and any changes to this list will be updated on the investor relations page.
Ligand Pharmaceuticals reported an insider stock sale by its chief financial officer, Octavio Espinoza. In the transaction dated 12/12/2025, he sold 1,804 shares of the company’s common stock at a price of $188.31 per share, coded as a sale in the regulatory report.
Following this transaction, Espinoza beneficially owns 26,186 shares of Ligand Pharmaceuticals common stock in direct ownership. The report is filed as an individual filing by one reporting person in his capacity as an officer and chief financial officer.
Ligand Pharmaceuticals Inc. Chief Executive Officer and director Todd C. Davis reported a bona fide gift of 130 shares of common stock on 12/04/2025.
The shares were given to a charitable entity and are reported at a price of $0.0, reflecting the gift nature of the transaction. Following this transfer, Davis directly beneficially owns 161,337 shares of Ligand common stock.
Ligand Pharmaceuticals (LGND) director John L. LaMattina reported same‑day option exercises and share sales. On 11/07/2025, he exercised 2,145 options at $66.13 and 2,034 options at $69.51, then sold 2,145 shares at $205.45 and 2,034 shares at $205.45. Following these transactions, he directly owned 30,724 shares. The options exercised were previously granted awards that had been adjusted in connection with the OmniAb Inc. separation and carried expiration dates of 05/25/2027 and 05/23/2026.
Ligand Pharmaceuticals (LGND) reported a strong Q3 2025. Total revenues and other income rose to $115.5 million from $51.8 million, led by royalties of $46.6 million and $58.2 million of contract revenue and other income.
Operating income improved to $54.9 million from $3.1 million, and non‑operating items added $86.2 million, including gains from equity‑method and other investments. Net income reached $117.3 million versus a loss a year ago, with diluted EPS of $5.68. Results included $53.1 million of income from the Pelthos transaction and higher royalties from products such as Filspari, Ohtuvayre, and Capvaxive.
The balance sheet expanded: cash and cash equivalents were $139.4 million and short‑term investments $525.1 million. The company issued $460.0 million of 2030 convertible senior notes, with $445.5 million reported as long‑term notes at quarter‑end. R&D expense increased to $21.0 million, reflecting portfolio activity. Stockholders’ equity rose to $950.2 million.
Ligand Pharmaceuticals (LGND) announced quarterly results by issuing a press release covering its financial performance for the three and nine months ended September 30, 2025.
The press release is furnished as Exhibit 99.1 and, in line with General Instruction B.2., the information is furnished rather than filed, which limits its treatment under the Exchange Act.
Ligand Pharmaceuticals (LGND): Form 4 insider transaction
Director John W. Kozarich reported open‑market sales of Ligand common stock on 11/03/2025 pursuant to a Rule 10b5‑1 trading plan adopted on March 07, 2025. Reported sales were executed in multiple trades: 84 shares at a weighted‑average price of $188.9968, 49 shares at $190.2579, 207 shares at $191.2494, and 127 shares at $192.3781. Following these transactions, the reporting person beneficially owned 44,588 shares, held directly. Prices reflect weighted averages across multiple executions within disclosed ranges.
Ligand Pharmaceuticals (LGND) reported an insider transaction by director John W. Kozarich. On 10/01/2025, he executed multiple open-market sales of common stock under a Rule 10b5-1 trading plan adopted on March 07, 2025.
Sales were small blocks of 24, 196, 155, and 92 shares at weighted-average prices of $177.6048, $178.4051, $180.0098, and $181.1838, respectively. Following these transactions, he directly beneficially owned 45,055 shares.
Footnotes state the prices reflect weighted averages across multiple trades within disclosed price ranges, with full breakdowns available upon request. The filing lists the reporting person as a Director with direct ownership.
Form 144 notice for Ligand Pharmaceuticals, Inc. (LGND) regarding proposed and recent sales of common stock. The filer reports a proposed sale of 467 shares through UBS Financial Services (Eleven Madison Avenue, New York) with an aggregate market value of $82,509.56 and an approximate sale date of 10/01/2025. The filing shows the securities were acquired on 06/09/2023 from the issuer and that payment was completed on that date. The filer also disclosed sales in the past three months by John Kozarich totaling 1,868 shares on 07/10/2025, 08/01/2025, and 09/02/2025, with reported gross proceeds of $116,750.00, $61,614.49, and $75,746.26, respectively. The filing includes the filer’s certification that they are not aware of undisclosed material adverse information.
Jason Aryeh, a director of Ligand Pharmaceuticals (LGND), reported the sale of 10,000 shares of Ligand common stock on 09/23/2025. The sales occurred in multiple transactions at weighted-average prices reported in three groupings: $170.4051 (range $169.6625–$170.6600), $170.9643 (range $170.6850–$171.6050), and $171.9237 (range $171.7250–$172.2400).
After these transactions Mr. Aryeh directly beneficially owned between 69,289 and 74,871 shares across the reported lines and retains indirect holdings of 51,594 shares through funds managed by JALAA Equities, LP/JLV Investments, LP and 5,025 shares held by a trust. The Form 4 was signed on 09/24/2025 by an attorney-in-fact.